Evidence map›Paper›PMID 42368451›Full record

ArticleFrontiers in cell and developmental biology2026

EphA2 sustains the adaptive response of colorectal organoids to chemotherapy.

Veronica Gatti, Gabriella Teresa Capolupo, Chiara Taffon, Andrea Marra, Giuseppe Perrone, Gianluca Masciana', Marco Caricato, Mario Cioce, Vito Michele Fazio

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Veronica GattiLaboratory of Molecular Medicine and Biotechnology, Department of Medicine, University of Campus- Biomedico of Rome, Rome, Italy.
Gabriella Teresa CapolupoUOC Chirurgia Colorettale, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Chiara TaffonResearch Unit of Anatomical Pathology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy.
Andrea MarraLaboratory of Molecular Medicine and Biotechnology, Department of Medicine, University of Campus- Biomedico of Rome, Rome, Italy.
Giuseppe PerroneResearch Unit of Anatomical Pathology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy.
Gianluca Masciana'UOC Chirurgia Colorettale, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Marco CaricatoUOC Chirurgia Colorettale, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Mario Cioce *Laboratory of Molecular Medicine and Biotechnology, Department of Medicine, University of Campus- Biomedico of Rome, Rome, Italy.
Vito Michele Fazio *Laboratory of Molecular Medicine and Biotechnology, Department of Medicine, University of Campus- Biomedico of Rome, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: EphA2 is highly expressed in colorectal cancer (CRC), and high EphA2 expression indicates a worse prognosis. We investigated EphA2 dynamics in a clinically relevant model: CRC patient-derived organoids (PDOs) treated with chemotherapy. Methods: We evaluated the number of EphA2-expressing cells and the Aldehyde dehydrogenase activity by flow cytometry, and analyzed EphA2 protein levels and phosphorylation status using Zn-Phos-tag gels and indirect ELISA. We employed siRNA to deplete the PDO cells of EphA2. Results: EphA2-positive cells form a stable subpopulation in organoid cultures that persists after oxaliplatin treatment. Phosphorylation of EphA2 at Ser897 increases with treatment and correlates with higher EphA2 levels. Silencing EphA2 or reducing Ser897 phosphorylation decreases organoid formation, suggesting chemosensitization. Some EphA2-positive cells show increased ALDH activity after chemotherapy, and EphA2-ALDH1A3 interaction has prognostic value in CRC. Discussion: Here, we discovered that EphA2-positive cells constitute a persistent, ALDH-positive cell subpopulation in CRC-PDOs that withstood exposure to oxaliplatin (OXA) and 5-fluorouracil (5-FU). The enforced suppression of EphA2 or diminished Ser897 stress results in a chemosensitization effect. This sheds further light on the role of EphA2 in the adaptive stress response of CRC.

Indexed as

ALDHchemoresistanceCRCDTPEphA2patient-derived-organoids

Identifiers

PMID42368451
PMCPMC13303685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.